| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 36 | 2023 | 187 | 13.480 |
Why?
|
| Food Hypersensitivity | 19 | 2023 | 57 | 11.160 |
Why?
|
| Rhinitis | 30 | 2023 | 165 | 10.350 |
Why?
|
| Asthma | 16 | 2023 | 138 | 8.600 |
Why?
|
| Nasal Polyps | 15 | 2023 | 62 | 5.200 |
Why?
|
| Microbiota | 10 | 2023 | 105 | 4.680 |
Why?
|
| Rhinitis, Allergic | 7 | 2023 | 24 | 4.540 |
Why?
|
| Hypersensitivity | 5 | 2023 | 48 | 3.480 |
Why?
|
| Coronavirus Infections | 6 | 2020 | 86 | 3.400 |
Why?
|
| Pneumonia, Viral | 6 | 2020 | 89 | 3.390 |
Why?
|
| Chronic Disease | 33 | 2023 | 495 | 3.210 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2023 | 180 | 3.170 |
Why?
|
| Dermatitis, Atopic | 4 | 2021 | 19 | 2.890 |
Why?
|
| Gastroesophageal Reflux | 4 | 2023 | 34 | 2.720 |
Why?
|
| Pandemics | 7 | 2020 | 236 | 2.550 |
Why?
|
| Betacoronavirus | 6 | 2020 | 75 | 2.540 |
Why?
|
| Humans | 84 | 2023 | 29337 | 2.310 |
Why?
|
| Child | 18 | 2023 | 1346 | 1.910 |
Why?
|
| Air Pollutants | 2 | 2021 | 12 | 1.560 |
Why?
|
| Eosinophilic Esophagitis | 2 | 2023 | 5 | 1.540 |
Why?
|
| Eczema | 2 | 2020 | 4 | 1.530 |
Why?
|
| Hypersensitivity, Immediate | 2 | 2023 | 5 | 1.440 |
Why?
|
| Healthcare Disparities | 2 | 2023 | 75 | 1.440 |
Why?
|
| Nose | 2 | 2020 | 36 | 1.360 |
Why?
|
| Female | 42 | 2022 | 16197 | 1.240 |
Why?
|
| Male | 40 | 2022 | 15621 | 1.240 |
Why?
|
| Eosinophilia | 7 | 2019 | 47 | 1.220 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2018 | 52 | 1.200 |
Why?
|
| Infant | 7 | 2021 | 531 | 1.140 |
Why?
|
| Adult | 27 | 2021 | 8601 | 1.130 |
Why?
|
| Colorectal Neoplasms | 7 | 2023 | 82 | 1.120 |
Why?
|
| Hospitalization | 2 | 2020 | 317 | 1.060 |
Why?
|
| Asthma, Aspirin-Induced | 3 | 2019 | 5 | 1.000 |
Why?
|
| Air Pollution | 2 | 2021 | 17 | 0.980 |
Why?
|
| Mutation | 4 | 2018 | 383 | 0.970 |
Why?
|
| Particulate Matter | 2 | 2021 | 22 | 0.960 |
Why?
|
| Olfaction Disorders | 3 | 2021 | 53 | 0.920 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2020 | 21 | 0.890 |
Why?
|
| Paranasal Sinuses | 6 | 2021 | 63 | 0.880 |
Why?
|
| Diet | 4 | 2021 | 174 | 0.870 |
Why?
|
| Middle Aged | 27 | 2021 | 9823 | 0.850 |
Why?
|
| Anaphylaxis | 1 | 2022 | 11 | 0.850 |
Why?
|
| Allergy and Immunology | 1 | 2021 | 2 | 0.830 |
Why?
|
| Nasal Mucosa | 2 | 2018 | 16 | 0.830 |
Why?
|
| Child, Preschool | 7 | 2021 | 642 | 0.830 |
Why?
|
| Gastrointestinal Diseases | 1 | 2022 | 43 | 0.820 |
Why?
|
| Sleep Wake Disorders | 1 | 2023 | 148 | 0.810 |
Why?
|
| Outpatients | 1 | 2021 | 52 | 0.800 |
Why?
|
| Comorbidity | 6 | 2022 | 498 | 0.800 |
Why?
|
| Certification | 1 | 2021 | 49 | 0.800 |
Why?
|
| Education, Medical | 1 | 2021 | 49 | 0.790 |
Why?
|
| Probiotics | 1 | 2021 | 20 | 0.780 |
Why?
|
| Corynebacterium | 1 | 2020 | 5 | 0.780 |
Why?
|
| Quality of Life | 4 | 2023 | 662 | 0.770 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2020 | 33 | 0.770 |
Why?
|
| Nasal Cavity | 1 | 2020 | 35 | 0.760 |
Why?
|
| Dyspnea | 1 | 2020 | 37 | 0.730 |
Why?
|
| Cohort Studies | 9 | 2022 | 1939 | 0.730 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 45 | 0.720 |
Why?
|
| Biological Therapy | 1 | 2019 | 5 | 0.710 |
Why?
|
| Desensitization, Immunologic | 1 | 2019 | 5 | 0.710 |
Why?
|
| Drug Hypersensitivity | 1 | 2019 | 17 | 0.710 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 77 | 0.690 |
Why?
|
| Severity of Illness Index | 10 | 2021 | 1113 | 0.680 |
Why?
|
| Eosinophils | 5 | 2019 | 47 | 0.670 |
Why?
|
| Retrospective Studies | 12 | 2023 | 3273 | 0.670 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 113 | 0.660 |
Why?
|
| Nocturnal Myoclonus Syndrome | 1 | 2018 | 7 | 0.650 |
Why?
|
| Polysomnography | 1 | 2018 | 92 | 0.640 |
Why?
|
| Aged | 19 | 2020 | 9448 | 0.630 |
Why?
|
| United States | 9 | 2023 | 2333 | 0.630 |
Why?
|
| Sleep | 1 | 2020 | 313 | 0.620 |
Why?
|
| Dietary Fiber | 1 | 2017 | 22 | 0.610 |
Why?
|
| Inflammation | 3 | 2017 | 344 | 0.610 |
Why?
|
| Sleep Disorders, Intrinsic | 1 | 2017 | 7 | 0.610 |
Why?
|
| Nasal Obstruction | 1 | 2017 | 5 | 0.610 |
Why?
|
| Age Factors | 7 | 2020 | 843 | 0.600 |
Why?
|
| Pollen | 1 | 2016 | 3 | 0.600 |
Why?
|
| Poverty | 1 | 2017 | 96 | 0.590 |
Why?
|
| Staphylococcal Infections | 1 | 2018 | 176 | 0.570 |
Why?
|
| Prospective Studies | 8 | 2023 | 1811 | 0.570 |
Why?
|
| Minority Groups | 1 | 2016 | 67 | 0.570 |
Why?
|
| Residence Characteristics | 1 | 2017 | 216 | 0.560 |
Why?
|
| Respiratory Tract Diseases | 1 | 2015 | 6 | 0.550 |
Why?
|
| Adolescent | 8 | 2021 | 2279 | 0.540 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 79 | 0.540 |
Why?
|
| Intermediate Filament Proteins | 1 | 2015 | 2 | 0.530 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2015 | 3 | 0.530 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2015 | 5 | 0.520 |
Why?
|
| Basophils | 1 | 2014 | 8 | 0.500 |
Why?
|
| Prevalence | 4 | 2023 | 487 | 0.490 |
Why?
|
| Otitis Media | 1 | 2013 | 5 | 0.480 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2013 | 6 | 0.480 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 10 | 0.470 |
Why?
|
| Pancreas | 3 | 2023 | 32 | 0.460 |
Why?
|
| Allergens | 3 | 2023 | 22 | 0.460 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2012 | 1 | 0.440 |
Why?
|
| Aspergillus fumigatus | 1 | 2012 | 3 | 0.440 |
Why?
|
| Antifungal Agents | 1 | 2012 | 36 | 0.420 |
Why?
|
| Risk Factors | 6 | 2021 | 2443 | 0.410 |
Why?
|
| Case-Control Studies | 4 | 2021 | 638 | 0.390 |
Why?
|
| Endoscopy | 7 | 2023 | 181 | 0.390 |
Why?
|
| Caregivers | 2 | 2022 | 143 | 0.370 |
Why?
|
| Illinois | 4 | 2019 | 241 | 0.350 |
Why?
|
| Disease Management | 2 | 2020 | 114 | 0.340 |
Why?
|
| Microsatellite Instability | 1 | 2008 | 6 | 0.340 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2020 | 100 | 0.340 |
Why?
|
| Genes, ras | 1 | 2008 | 13 | 0.340 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 56 | 0.330 |
Why?
|
| Aspirin | 3 | 2019 | 83 | 0.330 |
Why?
|
| South Africa | 2 | 2018 | 17 | 0.330 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2009 | 441 | 0.310 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2008 | 89 | 0.310 |
Why?
|
| Young Adult | 5 | 2020 | 1932 | 0.300 |
Why?
|
| Infant, Newborn | 2 | 2020 | 604 | 0.290 |
Why?
|
| Odds Ratio | 2 | 2018 | 285 | 0.280 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2005 | 10 | 0.270 |
Why?
|
| Surveys and Questionnaires | 4 | 2022 | 1184 | 0.270 |
Why?
|
| Carcinoma | 1 | 2005 | 57 | 0.260 |
Why?
|
| Schools | 2 | 2022 | 43 | 0.260 |
Why?
|
| Dust | 2 | 2022 | 6 | 0.260 |
Why?
|
| Sex Factors | 4 | 2020 | 496 | 0.240 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2020 | 56 | 0.230 |
Why?
|
| Time Factors | 4 | 2021 | 1616 | 0.230 |
Why?
|
| Food | 1 | 2023 | 28 | 0.230 |
Why?
|
| Feces | 1 | 2023 | 98 | 0.230 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2023 | 17 | 0.230 |
Why?
|
| Transcriptome | 1 | 2023 | 83 | 0.220 |
Why?
|
| Prognosis | 3 | 2020 | 840 | 0.220 |
Why?
|
| Shellfish Hypersensitivity | 1 | 2022 | 2 | 0.220 |
Why?
|
| Cockroaches | 1 | 2022 | 3 | 0.220 |
Why?
|
| Cytomegalovirus Infections | 1 | 2023 | 79 | 0.220 |
Why?
|
| Data Collection | 1 | 2023 | 107 | 0.220 |
Why?
|
| Logistic Models | 2 | 2020 | 407 | 0.220 |
Why?
|
| Interleukin-5 | 2 | 2019 | 10 | 0.220 |
Why?
|
| Treatment Outcome | 3 | 2020 | 3478 | 0.220 |
Why?
|
| Vulnerable Populations | 1 | 2022 | 24 | 0.210 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 328 | 0.210 |
Why?
|
| Biodiversity | 2 | 2018 | 37 | 0.200 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 138 | 0.200 |
Why?
|
| Staphylococcus aureus | 2 | 2018 | 85 | 0.200 |
Why?
|
| Urbanization | 1 | 2021 | 3 | 0.200 |
Why?
|
| Shellfish | 1 | 2021 | 3 | 0.200 |
Why?
|
| Environmental Exposure | 1 | 2021 | 15 | 0.200 |
Why?
|
| Ambulatory Care | 1 | 2021 | 75 | 0.200 |
Why?
|
| Bullying | 1 | 2020 | 4 | 0.200 |
Why?
|
| Particle Size | 1 | 2020 | 78 | 0.190 |
Why?
|
| Intubation | 1 | 2020 | 6 | 0.190 |
Why?
|
| Lipase | 1 | 2020 | 5 | 0.190 |
Why?
|
| Iran | 4 | 2009 | 36 | 0.190 |
Why?
|
| DNA, Ribosomal | 1 | 2020 | 12 | 0.190 |
Why?
|
| Histamine Antagonists | 1 | 2020 | 6 | 0.190 |
Why?
|
| Sulfides | 1 | 2020 | 12 | 0.190 |
Why?
|
| Acetates | 1 | 2020 | 19 | 0.190 |
Why?
|
| Quinolines | 1 | 2020 | 16 | 0.190 |
Why?
|
| DNA, Bacterial | 1 | 2020 | 48 | 0.190 |
Why?
|
| Albuterol | 1 | 2020 | 15 | 0.190 |
Why?
|
| Cyclopropanes | 1 | 2020 | 25 | 0.190 |
Why?
|
| Education, Distance | 1 | 2020 | 18 | 0.180 |
Why?
|
| Inpatients | 1 | 2021 | 141 | 0.180 |
Why?
|
| Obesity | 2 | 2020 | 291 | 0.180 |
Why?
|
| Parents | 1 | 2020 | 105 | 0.180 |
Why?
|
| Lung | 1 | 2020 | 154 | 0.170 |
Why?
|
| Body Mass Index | 2 | 2020 | 428 | 0.170 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 70 | 0.170 |
Why?
|
| Insurance Coverage | 1 | 2019 | 13 | 0.170 |
Why?
|
| Bacteroidetes | 1 | 2018 | 4 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 144 | 0.170 |
Why?
|
| Firmicutes | 1 | 2018 | 6 | 0.170 |
Why?
|
| Prednisone | 1 | 2018 | 67 | 0.170 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 101 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 107 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2018 | 34 | 0.160 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 364 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 80 | 0.160 |
Why?
|
| Disease Progression | 2 | 2018 | 787 | 0.160 |
Why?
|
| Epithelial Cells | 1 | 2018 | 87 | 0.160 |
Why?
|
| Neutrophils | 1 | 2018 | 117 | 0.160 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 4851 | 0.160 |
Why?
|
| Phenotype | 2 | 2016 | 355 | 0.160 |
Why?
|
| Income | 1 | 2017 | 74 | 0.160 |
Why?
|
| Macrophages | 1 | 2018 | 128 | 0.150 |
Why?
|
| Ethmoid Sinus | 1 | 2017 | 11 | 0.150 |
Why?
|
| Risk Assessment | 1 | 2020 | 679 | 0.150 |
Why?
|
| Radiation Injuries | 1 | 2017 | 34 | 0.150 |
Why?
|
| Chicago | 1 | 2020 | 865 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 142 | 0.150 |
Why?
|
| Raltegravir Potassium | 1 | 2016 | 9 | 0.150 |
Why?
|
| Drug Hypersensitivity Syndrome | 1 | 2016 | 2 | 0.150 |
Why?
|
| Syndrome | 1 | 2016 | 82 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2017 | 394 | 0.140 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 65 | 0.140 |
Why?
|
| Population Surveillance | 1 | 2016 | 116 | 0.130 |
Why?
|
| Reoperation | 1 | 2019 | 932 | 0.130 |
Why?
|
| Alkaline Phosphatase | 1 | 2015 | 16 | 0.130 |
Why?
|
| Immunoglobulin M | 1 | 2015 | 19 | 0.130 |
Why?
|
| Immunoglobulin A | 1 | 2015 | 19 | 0.130 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 18 | 0.130 |
Why?
|
| Alanine Transaminase | 1 | 2015 | 21 | 0.130 |
Why?
|
| Respiratory Mucosa | 1 | 2014 | 4 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 129 | 0.120 |
Why?
|
| Cytokines | 1 | 2015 | 347 | 0.120 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 26 | 0.110 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 81 | 0.110 |
Why?
|
| Depression | 1 | 2017 | 465 | 0.110 |
Why?
|
| Cystic Fibrosis | 1 | 2012 | 12 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2018 | 957 | 0.110 |
Why?
|
| Genes, p53 | 1 | 2009 | 17 | 0.090 |
Why?
|
| CpG Islands | 1 | 2009 | 34 | 0.090 |
Why?
|
| Geography | 1 | 2009 | 22 | 0.090 |
Why?
|
| Food Supply | 1 | 2009 | 14 | 0.090 |
Why?
|
| Leukocyte Count | 2 | 2019 | 92 | 0.090 |
Why?
|
| Molecular Biology | 1 | 2009 | 14 | 0.090 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 938 | 0.080 |
Why?
|
| Biomarkers | 3 | 2017 | 689 | 0.080 |
Why?
|
| Postoperative Period | 2 | 2018 | 288 | 0.070 |
Why?
|
| Esophageal Achalasia | 1 | 2006 | 19 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 959 | 0.070 |
Why?
|
| Family Health | 1 | 2005 | 37 | 0.070 |
Why?
|
| Age of Onset | 1 | 2005 | 108 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2005 | 132 | 0.060 |
Why?
|
| Registries | 1 | 2005 | 188 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 189 | 0.060 |
Why?
|
| Celecoxib | 1 | 2023 | 5 | 0.060 |
Why?
|
| Bicycling | 1 | 2023 | 2 | 0.060 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2023 | 6 | 0.060 |
Why?
|
| Ki-67 Antigen | 1 | 2023 | 13 | 0.060 |
Why?
|
| Ganciclovir | 1 | 2023 | 26 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2023 | 30 | 0.060 |
Why?
|
| Caco-2 Cells | 1 | 2023 | 53 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2023 | 95 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2023 | 76 | 0.060 |
Why?
|
| Databases as Topic | 1 | 2023 | 19 | 0.060 |
Why?
|
| ErbB Receptors | 1 | 2023 | 72 | 0.060 |
Why?
|
| Information Dissemination | 1 | 2023 | 23 | 0.060 |
Why?
|
| Dermatophagoides pteronyssinus | 1 | 2022 | 2 | 0.060 |
Why?
|
| Pyroglyphidae | 1 | 2022 | 3 | 0.060 |
Why?
|
| Antigens, Dermatophagoides | 1 | 2022 | 3 | 0.060 |
Why?
|
| Self Efficacy | 1 | 2022 | 57 | 0.050 |
Why?
|
| Animals | 2 | 2022 | 4552 | 0.050 |
Why?
|
| Taste Disorders | 1 | 2021 | 5 | 0.050 |
Why?
|
| Symptom Assessment | 1 | 2020 | 21 | 0.050 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2019 | 28 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2019 | 65 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 194 | 0.040 |
Why?
|
| Smoking | 1 | 2020 | 194 | 0.040 |
Why?
|
| Metaplasia | 1 | 2018 | 11 | 0.040 |
Why?
|
| RAW 264.7 Cells | 1 | 2018 | 4 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 20 | 0.040 |
Why?
|
| Precancerous Conditions | 1 | 2018 | 22 | 0.040 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 16 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2018 | 55 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2018 | 21 | 0.040 |
Why?
|
| Recurrence | 1 | 2018 | 350 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2018 | 201 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 264 | 0.040 |
Why?
|
| Basement Membrane | 1 | 2017 | 12 | 0.040 |
Why?
|
| Lysophospholipase | 1 | 2017 | 1 | 0.040 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2018 | 79 | 0.040 |
Why?
|
| Eosinophil Cationic Protein | 1 | 2017 | 2 | 0.040 |
Why?
|
| Turbinates | 1 | 2017 | 4 | 0.040 |
Why?
|
| Fibrosis | 1 | 2017 | 39 | 0.040 |
Why?
|
| Chemokine CCL11 | 1 | 2017 | 8 | 0.040 |
Why?
|
| Edema | 1 | 2017 | 38 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2017 | 32 | 0.040 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2017 | 36 | 0.040 |
Why?
|
| Drug Eruptions | 1 | 2016 | 10 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2017 | 58 | 0.040 |
Why?
|
| Nasal Lavage Fluid | 1 | 2015 | 1 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 389 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 47 | 0.030 |
Why?
|
| Immunoassay | 1 | 2015 | 41 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 130 | 0.030 |
Why?
|
| Developing Countries | 1 | 2014 | 22 | 0.030 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2014 | 34 | 0.030 |
Why?
|
| Global Health | 1 | 2014 | 55 | 0.030 |
Why?
|
| Environment | 1 | 2014 | 46 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 74 | 0.030 |
Why?
|
| Mice | 1 | 2018 | 1607 | 0.030 |
Why?
|
| Intestines | 1 | 2014 | 107 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2014 | 100 | 0.030 |
Why?
|
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2013 | 2 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2013 | 8 | 0.030 |
Why?
|
| Syndecan-1 | 1 | 2013 | 8 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2013 | 29 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2013 | 29 | 0.030 |
Why?
|
| Antibodies | 1 | 2013 | 65 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2013 | 198 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 770 | 0.030 |
Why?
|
| Life Style | 1 | 2014 | 211 | 0.030 |
Why?
|
| Gene Expression | 1 | 2013 | 226 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 391 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2009 | 52 | 0.020 |
Why?
|
| Mass Screening | 1 | 2009 | 177 | 0.020 |
Why?
|
| Manometry | 1 | 2006 | 18 | 0.020 |
Why?
|
| Neurotoxins | 1 | 2006 | 19 | 0.020 |
Why?
|
| Chest Pain | 1 | 2006 | 24 | 0.020 |
Why?
|
| Catheterization | 1 | 2006 | 51 | 0.020 |
Why?
|
| Deglutition Disorders | 1 | 2006 | 44 | 0.020 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2006 | 34 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 96 | 0.020 |
Why?
|
| Age Distribution | 1 | 2005 | 94 | 0.020 |
Why?
|
| Radiography | 1 | 2006 | 678 | 0.020 |
Why?
|
| Incidence | 1 | 2005 | 756 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 1830 | 0.010 |
Why?
|